Recently, CNBC Make It profiled the New York City bar, Adriaen Block, where customers can choose from an entire menu of CBD-infused cocktails and food items, like a cheeseburger with CBD-infused sauce. (This reporter sampled the restaurant's CBD-infused menu items, which were tasty — the CBD oil did not overpower — and I did feel a bit relaxed afterward, though the alcohol could have played a role in that.)
The theoretical logic is there, Gerdeman says. What exactly is that thinking? Well, there are a few different ways CBD could help regulate pain—by increasing your natural endocannabinoids, decreasing your inflammatory response, and desensitizing your pain receptors (although it’s still unclear whether this stands when absorbed topically compared to orally).
CBD products have become increasingly popular in recent years, as more and more producers market CBD as the new "it" drug for the health and wellness set — one that has been touted as a pain reliever and a treatment for anxiety, among other potential applications. Last year, consumer sales of CBD products topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years.
Although contaminants come in various shapes and forms, most are relatively easy to detect, because many professional analytical labs exist that routinely screen for such contaminants in, for example, food crops, imported medicinal plants, or edible oils. The standard lab methods, as described in Pharmacopoeia monographs (e.g., USP, EP) or food regulations, could simply be applied to CBD oils, after some minor validation studies. For example, the detection of heavy metals or pesticides present in CBD oil does not significantly differ from the same analysis in, say, a shipment of olive oil. The only analysis that is not yet standard procedure in most analytical labs is the quantification of cannabinoids. Because cannabinoids are only found (with few exceptions ) in the cannabis plant, specific analytical methodology must be developed to properly determine the cannabinoid composition of the many CBD products available.
Cannabidiol is currently a class B1 controlled drug in New Zealand under the Misuse of Drugs Act. It is also a prescription medicine under the Medicines Act. In 2017 the rules were changed so that anyone wanting to use it could go to the Health Ministry for approval. Prior to this, the only way to obtain a prescription was to seek the personal approval of the Minister of Health.